BRIEF published on 09/09/2024 at 23:01, 2 months 11 days ago Statement by Marc de Garidel on Abivax's 2024 Half-Year Financial Report Financial Report Abivax Transparency IFRS Heritage
BRIEF published on 09/09/2024 at 22:40, 2 months 11 days ago ABIVAX presents its 2024 half-year results Cybersecurity Abivax Half-year Results Internal Control Failures
BRIEF published on 09/09/2024 at 22:06, 2 months 11 days ago Abivax financial results for the first half of 2024 Financial Results Biotechnology Abivax First Half Of 2024 Immune Mechanisms
PRESS RELEASE published on 09/09/2024 at 22:01, 2 months 11 days ago Abivax presents first-half 2024 financial results Abivax presents first-half 2024 financial results with a cash balance of EUR 222M at June 30, 2024. The company focuses on developing therapies for chronic inflammatory diseases Financial Results Abivax Therapeutics Chronic Inflammatory Diseases EUR 222M
BRIEF published on 08/29/2024 at 18:05, 2 months 22 days ago ABIVAX: Status of shares and voting rights as of July 31, 2024 Euronext Paris Voting Rights Actions Abivax Regulatory
BRIEF published on 08/06/2024 at 08:35, 3 months 15 days ago Abivax Reaches Key Milestone with Recruitment of 600 Patients for Phase 3 ABTECT Trial Patient Recruitment Abivax Obefazimod Ulcerative Colitis Clinical Test
PRESS RELEASE published on 08/06/2024 at 08:30, 3 months 15 days ago Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone Abivax announces ABTECT Phase 3 Trial surpasses 600-patient enrollment milestone, on track for full enrollment by early Q1 2025. Trial trends align with previous observations Abivax Obefazimod Ulcerative Colitis ABTECT Phase 3 Trial Enrollment Milestone
BRIEF published on 07/23/2024 at 18:05, 3 months 28 days ago ABIVAX: Number of shares and voting rights as of June 30, 2024 Voting Rights Euronext Actions AMF Abivax
BRIEF published on 07/23/2024 at 18:05, 3 months 28 days ago ABIVAX: Half-yearly review of the liquidity contract as of June 30, 2024 Liquidity Contract Actions Financial Transactions Abivax First Half Of 2024
BRIEF published on 07/22/2024 at 09:51, 3 months 30 days ago Threshold crossing by Deep Track Biotechnology Master Fund Voting Rights Abivax Crossing Threshold Off-market Acquisition Deep Track Biotechnology
Published on 11/21/2024 at 16:30, 1 hour 6 minutes ago The Rise of DINKs: Dual-Income Couples Without Kids Redefine Financial Priorities in America
Published on 11/21/2024 at 16:01, 1 hour 35 minutes ago Career Certified Extends Its Investment in the Fast-Growing Architecture, Engineering, and Construction (AEC) Professionals Market with Acquisition of My Contractors License
Published on 11/21/2024 at 16:00, 1 hour 36 minutes ago Financial Independence Group Announces Exclusive Partnership With Power of Zero and Tax-Free Retirement Expert David McKnight
Published on 11/21/2024 at 16:00, 1 hour 36 minutes ago Wiz Acquires Dazz to Revolutionize Cloud Security Remediation
Published on 11/21/2024 at 16:00, 1 hour 36 minutes ago Isaac Ullatil Joins Wellstack Board of Directors
Published on 11/21/2024 at 15:41, 1 hour 54 minutes ago Edison issues report on Murray Income Trust (MUT)
Published on 11/21/2024 at 15:24, 2 hours 12 minutes ago Form 8.3 - The Vanguard Group, Inc.: International Paper Company
Published on 11/21/2024 at 15:23, 2 hours 13 minutes ago Form 8.3 - The Vanguard Group, Inc.: Centamin plc
Published on 11/21/2024 at 15:22, 2 hours 14 minutes ago Form 8.3 - The Vanguard Group, Inc.: TI Fluid Systems plc
Published on 11/21/2024 at 06:58, 10 hours 38 minutes ago Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 22 hours 16 minutes ago Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 23 hours 51 minutes ago MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 23 hours 51 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 9 hours ago Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo
